HC Wainwright reiterated their buy rating on shares of ArriVent BioPharma (NASDAQ:AVBP - Free Report) in a research report report published on Thursday morning, Benzinga reports. They currently have a $25.00 target price on the stock.
Other equities analysts have also recently issued research reports about the company. The Goldman Sachs Group assumed coverage on ArriVent BioPharma in a report on Tuesday, February 20th. They issued a buy rating and a $27.00 price objective for the company. Jefferies Financial Group began coverage on shares of ArriVent BioPharma in a research report on Tuesday, February 20th. They set a buy rating and a $35.00 price target on the stock. Finally, Citigroup initiated coverage on shares of ArriVent BioPharma in a research note on Tuesday, February 20th. They set a buy rating and a $30.00 price objective on the stock.
Read Our Latest Stock Analysis on ArriVent BioPharma
ArriVent BioPharma Stock Up 3.6 %
Shares of AVBP stock traded up $0.63 during trading on Thursday, reaching $17.99. The company's stock had a trading volume of 30,615 shares, compared to its average volume of 179,817. ArriVent BioPharma has a one year low of $14.35 and a one year high of $25.95. The firm's fifty day moving average is $17.88.
Hedge Funds Weigh In On ArriVent BioPharma
A hedge fund recently bought a new stake in ArriVent BioPharma stock. BNP Paribas Financial Markets acquired a new position in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 4,659 shares of the company's stock, valued at approximately $83,000. Institutional investors own 9.48% of the company's stock.
About ArriVent BioPharma
(
Get Free Report)
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
Read More
Before you consider ArriVent BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.
While ArriVent BioPharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
